论文信息 - First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study - 字舞流文

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

B. Han | K. Li | P. Yu | Y. Shu | N. Wu | X. Liu | S. Zhao | Xiaoqing Liu | Yan Sun | C. Ding | Lvhua Wang | W. Li | Yan Sun | Xiaohong Han | C. Yao | Y. Sun | Y. Song | H. Zhang | Y. Shi | X. Song | F. Tan | Kai Li | B. Han | Z. Ma | Yuankai Shi | Yunpeng Liu | L. Wang | G. Chen | Y. Lin | W. Song | X. Ye | L. Ding | Ying-qiu Song | X. Han | J. Feng | Y. P. Liu | X. Ren | S. C. Zhang | Y. Song | K. Li | K. Li | S. Zhao | Y. Song | S. Zhao | K. Li | Gongyan Chen | Baohui Han | S. Zhang